---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086086"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:21:05.370554+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioXcel Q2 2024 IGALMI net revenue up 141% YoY to $1.1M; net loss narrows to $8.3M

## Summary
- IGALMI net revenue $1.1M (+141% YoY, +90% sequentially) on increased psychiatric clinic contracting.
- Net loss $8.3M vs $53.5M in Q2 2023; operating cash used $23.2M; cash $56.3M at June 30.
- Planning SERENITY At-Home Phase 3 for BXCL501 in agitation with bipolar/schizophrenia; TRANQUILITY In-Care Phase 3 for Alzheimer's agitation.
- IGALMI PMR study showed no tachyphylaxis/tolerance/withdrawal; no serious adverse events reported.
- Received USPTO Notice of Allowance for new patent expiring 2043, expected as 11th Orange Book listing for IGALMI.

## SEC filing metadata
- accession: 0001104659-24-086086
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/0001104659-24-086086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924086086/tm2420782d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086086
- JSON: https://secwatch.observer/filing/0001104659-24-086086.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.